期刊文献+

新辅助化疗前后Ki-67的表达改变在预测不同分子分型乳腺癌化疗疗效中的作用 被引量:12

Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes
原文传递
导出
摘要 目的 分析不同分子分型乳腺癌患者的临床病理特征,了解新辅助治疗前后Ki-67的表达变化对不同分子分型乳腺癌患者预后的预测作用.方法 回顾性分析2007年8月至2008年8月天津医科大学肿瘤医院乳腺外科收治的178例初治乳腺癌患者的临床资料,术前均经粗针吸穿刺活检证实为乳腺癌,并给予蒽环类联合紫杉类药物新辅助化疗.根据免疫组化染色结果进行分子分型,分析不同分子分型乳腺癌患者的临床病理特征以及Ki-67表达变化对不同分型乳腺癌患者预后的影响.结果 Luminal A型42例,Luminal B型78例,人表皮生长因子受体2(HER-2)过表达型22例,三阴性36例.新辅助化疗后,达到病理完全缓解(pCR)的患者27例,占15.2%,其中Luminal A型、Luminal B型、HER-2过表达型以及三阴性乳腺癌患者的pCR率分别为14.3%、10.3%、18.2%和25.0%,差异有统计学意义(P =0.040).在Luminal A型和三阴性乳腺癌中,新辅助治疗后Ki-67表达降低的患者无病生存率明显提高(P=0.019和P=0.022).Cox多因素分析的结果显示,临床分期、新辅助化疗的疗效、新辅助化疗后Ki-67的表达情况是影响三阴性乳腺癌患者无病生存率的独立因素(均P<0.05).结论 新辅助化疗后Ki-67的表达情况是影响三阴性乳腺癌患者无病生存率的独立因素. Objective This study was conducted to analyze the Ki-67 expression before and after neoadjuvant chemotherapy and clinicopathological characteristics of different biological breast cancer phenotypes.The significance and prognostic predictive value of the changes of Ki-67 expression in different biological breast cancer phenotypes were analyzed.Methods A regression analysis was performed on 178 patients with invasive breast carcinoma who accepted neoadjuvant chemotherapy at Tianjin Medical University Cancer Institute and Hospital from August 2007 to August 2008.These patients were subtyped by hormone receptor status and HER-2 status.The Ki-67 index (percentage of Ki-67-positive cancer cell nuclei) was determined by immunohistochemistry.The prognostic value of Ki-67 index for disease-free survival (DFS) in different biological breast cancer phenotypes was analyzed using Kaplan-Meier survival and multivariable Cox regression.Results The overall pathologic CR (pCR) rate,defined as no invasive residuals in the breast and axilla,was 15.2%.The highest pCR rate of 25.0% was observed in the TNBC patients,which was 14.3%,10.3% and 18.2% in the luminal A,luminal B and HER2 overexpressing patients,respectively (P =0.040).The changes of Ki-67 expression in pre-NAC and post-NAC patients showed a prognostic significance in luminal A and TNBC (P =0.019 and P =0.022,respectively) cases.Clinical stage,the efficacy of NAC,and changes of Ki-67 expression between pre-and post-NAC were independent prognostic factors in TNBC patients who did not achieve pCR.Conclusions The Ki-67 expression after neoadjuvant chemotherapy is an independent prognostic factor affecting the disease-free survival (DFS) in TNBC patients who have not achieved pCR.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2014年第9期671-676,共6页 Chinese Journal of Oncology
基金 天津市重大科技专项(工程)项目抗癌重大科技专项资助( 12ZCDZSY15700 )
关键词 乳腺肿瘤 新辅助化疗 KI-67 分子分型 Breast neoplasms Neoadjuvant chemotherapy Ki-67 Molecular typing
  • 相关文献

参考文献17

  • 1Park BW,Park S,Park HS,et al.Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes[J].Breast Cancer Res Treat,2012,133 (2):741-751.
  • 2Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,131(1):18-43.
  • 3Perou CM,S(o)rlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,17,406(6797):747-752.
  • 4S(o)rlie T.Molecular portraits of breast cancer:tumour subtypes as distinct disease entities[J].Eur J Cancer,2004,40(18):2667-2675.
  • 5Brenton JD,Carey LA,Ahmed AA,et al.Molecular classification and molecular forecasting of breast cancer:ready for clinical application?[J].J Clin Oncol,2005,23(29):7350-7360.
  • 6Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer[J].J Clin Oncol,2006,24(36):5652-5657.
  • 7Baak JP,Gudlaugsson E,Skaland I,et al.Proliferation is the strongest prognosticator in node-negative breast cancer:significance,error sources,alternatives and comparison with molecular prognostic markers[J].Breast Cancer Res Treat,2009,115(2):241-254.
  • 8Dowsett M,Smith IE,Ebbs SR,et al.Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer[J].J Natl Cancer Inst,2007,99(2):167-170.
  • 9Harper-Wymne C,Ross G,Sacks N,et al.Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women:a pilot study for breast cancer prevention[J].Cancer Epidemiol Biomarkers Prey,2002,11(7):614-621.
  • 10Ishitobi M,Okumura Y,Arima N,et al.Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence[J].Ann Surg Oncol,2013,20(6):1886-1892.

同被引文献91

  • 1朱亚东.乳腺癌术后无瘤生存率的影响因素及腋窝淋巴结检测数目的临床意义[J].实用癌症杂志,2014,29(2):222-225. 被引量:8
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1534
  • 3Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast canc- er:prognostic and predictive potential[J]. Lancet Oneol, 2010, 11(2) : 174-183.
  • 4Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer., recommendations from the International Ki67 in Breast Cancer working group [J]. J Natl Cancer Inst, 2011, 103 (22) : 1656-1664.
  • 5Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumors of the breast[M]. Lyon:IARC Press, 2012:8-168.
  • 6Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub- types--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer[J]. Ann Oncol, 2011, 22 (8) : 1736-1747.
  • 7Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer[J]. Br J Cancer, 2012, 106(2) : 383-388.
  • 8Konsti J, Lundin M, Linder N, et al. Effect of image compres- sion and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium [J ]. Diagn Pathol, 2012, 7.29.
  • 9Voros A, Csorgo E, Nyari T, et at. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assess- ment on core biopsies of breast cancer patients and its potential clinical implications [J]. Pathobiology, 2013, 80(3) :111-118.
  • 10Gudlaugsson E, Skaland I, Janssen EA, et al. Comparison of the effect of different techniques for measurement of Ki67 prolifera- tion on reproducibility and prognosis prediction accuracy in breast cancer [J]. Histopathology, 2012, 61(6):1134-1144.

引证文献12

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部